Citation: | Yan Xing, Zebo Yu, Dandan Xu, Tingxi Zhan, Wenjun Que, Jing Wang. A hemolysis verified to be induced by anti-meropenem[J]. Blood&Genomics, 2023, 7(1): 61-66. doi: 10.46701/BG.2023012022028 |
[1] |
Elgebaly AS, Fathy SM, Elmorad MB, et al. Blood transfusion and lung surgeries in pediatric age group: a single center retrospective study[J]. Ann Card Anaesth, 2020, 23(2): 149−153. doi: 10.4103/aca.ACA_210_18
|
[2] |
Garratty G. Drug-induced immune hemolytic anemia[J]. Hematology Am Soc Hematol Educ Program, 2009: 73−79. doi: 10.1182/asheducation-2009.1.73
|
[3] |
Renard D, Rosselet A. Drug-induced hemolytic anemia: pharmacological aspects[J]. Transfus Clin Biol, 2017, 24(3): 110−114. doi: 10.1016/j.tracli.2017.05.013
|
[4] |
Salama A. Drug-induced immune hemolytic anemia[J]. Expert Opin Drug Saf, 2009, 8(1): 73−79. doi: 10.1517/14740330802577351
|
[5] |
Oka S, Shiragami H, Nohgawa M. Intravascular hemolytic anemia in a patient with antibodies related to meropenem[J]. Intern Med, 2015, 54(10): 1291−1295. doi: 10.2169/internalmedicine.54.3385
|
[6] |
Garratty G. Immune hemolytic anemia caused by drugs[J]. Expert Opin Drug Saf, 2012, 11(4): 635−642. doi: 10.1517/14740338.2012.678832
|
[7] |
Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007[J]. Immunohematology, 2014, 30(2): 66−79.
|
[8] |
Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia[J]. Immunohematology, 2014, 30(2): 85−94
|
[9] |
Gniadek TJ, Arndt PA, Leger RM, et al. Drug-induced immune hemolytic anemia associated with anti-vancomycin complicated by a paraben antibody[J]. Transfusion, 2018, 58(1): 181−188. doi: 10.1111/trf.14362
|
[10] |
Okuno T, Kondelis N. Evaluation of dithiothreitol (DTT) for inactivation of IgM antibodies[J]. J Clin Pathol, 1978, 31(12): 1152−1155. doi: 10.1136/jcp.31.12.1152
|
[11] |
Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes[J]. Immunohematology, 2014, 30(2): 44–54.
|
[12] |
Leger RM, Arndt PA, Garratty G. Serological studies of piperacillin antibodies[J]. Transfusion, 2008, 48(11): 2429−2434. doi: 10.1111/j.1537-2995.2008.01852.x
|
[13] |
Garratty G. Review: drug-induced immune hemolytic anemia--the last decade[J]. Immunohematology, 2004, 20(3): 138–146.
|
[14] |
Kumar S, Bansal R, Bansal P, et al. Ceftriaxone-induced hemolytic anemia: a rare case report[J]. Perm J, 2020, 24: 19.088. doi: 10.7812/TPP/19.088
|
[15] |
De Wilde M, Speeckaert M, Callens R, et al. Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of 'chronic Lyme disease'[J]. Acta Clin Belg, 2017, 72(2): 133−137. doi: 10.1080/17843286.2016.1180829
|
[16] |
Leicht HB, Weinig E, Mayer B, et al. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature[J]. BMC Pharmacol Toxicol, 2018, 19(1): 67. doi: 10.1186/s40360-018-0257-7
|